Author: Härter, Georg; Spinner, Christoph D.; Roider, Julia; Bickel, Markus; Krznaric, Ivanka; Grunwald, Stephan; Schabaz, Farhad; Gillor, Daniel; Postel, Nils; Mueller, Matthias C.; Müller, Markus; Römer, Katja; Schewe, Knud; Hoffmann, Christian
Title: COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients Cord-id: 1q1x71xb Document date: 2020_5_11
ID: 1q1x71xb
Snippet: INTRODUCTION: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. METHODS: Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome. RESULTS: Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild c
Document: INTRODUCTION: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. METHODS: Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome. RESULTS: Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir. CONCLUSIONS: This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.
Search related documents:
Co phrase search for related documents- absolute cell and admission rate: 1
- acute respiratory syndrome and admission rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory syndrome and lopinavir standard care ritonavir: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome and lopinavir trial: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory syndrome and lung infiltrate: 1, 2, 3, 4, 5, 6
- admission rate and lopinavir trial: 1
Co phrase search for related documents, hyperlinks ordered by date